What are cancer patients willing to pay for prophylactic epoetin alfa?
- 15 December 1998
- Vol. 83 (12) , 2588-2596
- https://doi.org/10.1002/(sici)1097-0142(19981215)83:12<2588::aid-cncr26>3.0.co;2-m
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia.Journal of Clinical Oncology, 1997
- When Do the "Dollars" Make Sense?Medical Decision Making, 1996
- ANEMIA OF CANCERHematology/Oncology Clinics of North America, 1996
- Assessing the Economic Value of a New AntidepressantPharmacoEconomics, 1995
- Transfusion requirements, risks, and costs for patients with malignancyTransfusion, 1995
- Willingness-to-Pay as a Measure of BenefitsMedical Care, 1991
- Red blood cell transfusions for anemiaSeminars in Oncology Nursing, 1990
- Risk Reduction From Low Osmolality Contrast Media: What Do Patients Think It is WorthMedical Care, 1990
- Treatment of advanced non‐small cell lung cancer with cisplatin, 5‐fluorouracil, and mitomycin CCancer, 1988
- Anemia in CancerCancer Investigation, 1985